SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001047469-17-002384
Filing Date
2017-04-06
Accepted
2017-04-06 16:09:08
Documents
5
Period of Report
2017-05-23
Effectiveness Date
2017-04-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2231618zdef14a.htm DEF 14A 371533
2 G342833.JPG g342833.jpg GRAPHIC 12219
3 G241589.JPG g241589.jpg GRAPHIC 7677
4 G101602BGI001.GIF g101602bgi001.gif GRAPHIC 141989
5 G101602BGI002.GIF g101602bgi002.gif GRAPHIC 67204
  Complete submission text file 0001047469-17-002384.txt   688607
Mailing Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152
Business Address 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 248-980-6538
Gemphire Therapeutics Inc. (Filer) CIK: 0001638287 (see all company filings)

IRS No.: 472389984 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37809 | Film No.: 17746062
SIC: 2834 Pharmaceutical Preparations